Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
ACTRIMS 2023
ISC 2023
EHC 2022
AES 2022
WSC 2022
ECTRIMS 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Antibodies
3:08
Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study
Barry Singer
• 28 Feb 2023
3:33
Impact of natalizumab on chronic active MS lesions
Laura Airas
• 16 Feb 2023
8:37
Prevention medication for pediatric migraine: should it be re-examined?
Massimiliano Valeriani
• 15 Dec 2022
1:26
Update on EHF guideline for anti-CGRP antibodies for migraine prevention
Raffaele Ornello
• 5 Dec 2022
2:22
Real-world data to enhance migraine clinical trials
Raffaele Ornello
• 5 Dec 2022
1:49
Switching erenumab to fremanezumab in chronic migraine: results of a real-world study
Valeria Caponnetto
• 14 Dec 2022
1:30
Preliminary data on the use of anti-CGRP mAbs in pediatric migraine
Massimiliano Valeriani
• 15 Dec 2022
8:29
Real-world data on anti-CGRP monoclonal antibodies
Gisela Terwindt
• 12 Dec 2022
3:10
Natalizumab: a strategy for immunization to avoid delays of treatment onset in highly active MS
Mar Tintoré
• 4 Nov 2022
2:21
METEOROID: Phase III trial of satralizumab in patients with MOGAD
Kazuo Fujihara
• 28 Oct 2022
5:25
Current diagnostic and treatment measures for AQP4-IgG-positive NMOSD
Kazuo Fujihara
• 28 Oct 2022
3:00
Unmet needs in the diagnostics and treatment of NMOSD
Kazuo Fujihara
• 28 Oct 2022
1:32
New agents under investigation to treat AQP4-positive NMOSD
Kazuo Fujihara
• 28 Oct 2022
4:32
Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS
João José Cerqueira
• 28 Oct 2022
1:28
The benefits of immune reconstitution therapy in MS
Celia Oreja-Guevara
• 28 Oct 2022
1:46
Current recommendations on MS treatment during pregnancy
Eva Kubala Havrdová
• 27 Oct 2022
1
2
3
4
5
…
15
Next